Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 13, 2023

Real-World Outcomes of Trastuzumab Deruxtecan in Patients With Advanced HER2-Positive Breast Cancer With Active Brain Metastasis or Progressive Extracranial Disease



Additional Info

A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone
ESMO Open 2023 Oct 20;8(6)102033, J Pearson, A Khan, T Bhogal, H Wong, A Law, S Mills, N Santamaria, J Bishop, J Cliff, D Errington, A Hall, C Hart, Z Malik, R Sripadam, H Innes, H Flint, G Langton, E Ahmed, R Jackson, C Palmieri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading